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Osteoimmunology is field of research dedicated to the study of the interactions between 
the immune system and bone. Among the cells of the immune system that regulate the 
skeleton in health and disease are T lymphocytes, T cells secrete inflammatory/osteo-
clastogenic cytokines such as RANKL, TNF, and IL-17, as well as factors that stimulate 
bone formation, including Wnt ligands. In addition, T cells regulate the differentiation 
and life span of stromal cells via CD40L and other costimulatory molecules expressed 
on their surface. Consensus exists that parathyroid hormone (PTH) induces bone loss 
by increasing the production of RANKL by osteocytes and osteoblast. However, new 
evidence suggests that PTH expands Th17 cells and increases IL-17 levels in mice and 
humans. Studies in the mouse of further shown that Th17 cell produced IL-17 acts as an 
“upstream cytokine” that increases the sensitivity of osteoblasts and osteocytes to PTH. 
As a result, PTH stimulates osteocytic and osteoblastic release of RANKL. Therefore, 
PTH cause bone loss only in the presence of IL-17 signaling. This article reviews the 
evidence that the effects of PTH are mediated not only by osteoblasts and osteocytes, 
but also T cells and IL-17.
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iNtrODUctiON
Parathyroid hormone (PTH) is an important regulator of calcium and phosphorus concentrations 
in extracellular fluid. Physiologic levels of circulating PTH are essential for maintaining serum and 
urinary calcium levels within their normal range. Chronic excessive PTH production is a cause 
of skeletal and extra skeletal disease. Secondary hyperparathyroidism has been implicated in the 
pathogenesis of senile osteoporosis (1), while primary hyperparathyroidism (PHPT) is associated 
with accelerated bone loss (2) and osteoporosis (3–5).
Primary and secondary hyperparathyroidism are mimicked by continuous PTH (cPTH) infusion. 
cPTH and PHPT increase bone turnover in trabecular and cortical bone, as evidenced by elevations 
in histomorphometric and biochemical markers of resorption and formation (6–8), whereas PHPT 
and cPTH treatment cause cortical bone loss by enhancing endosteal resorption through stimulation 
of osteoclast formation, activity, and life span (3, 8, 9). Severe chronic elevations of PTH levels may 
also lead to trabecular bone loss (3, 8), although PHPT and cPTH treatment often induce a modest 
increase in cancellous bone (4–6, 10).
The effects of cPTH on bone result from its binding to the PTH/PTH-related protein (PTHrP) 
receptor (PPR or PTHR1), which is expressed not only on BM stromal cells (SCs), osteoblasts, and 
osteocytes (11, 12) but also on T cells (13) and macrophages (14). SCs and osteoblasts were the 
first targets of PTH to be identified, and earlier consensus developed that the catabolic effect of 
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cPTH is mostly mediated by enhanced production of RANKL 
and decreased production of OPG by SCs and osteoblasts 
(15–17). More recent studies in mice with deletion and/or 
overexpression of PPR and RANKL in osteocytes (12, 18–20) 
lead to the recognition that osteocytes represent essential targets 
of PTH in bone, and that increased production of RANKL by 
osteocytes plays an important role in cPTH-induced bone loss 
(12, 19). However, some reports have ascribed a key role to 
OB produced RANKL (21). Moreover, studies have also shown 
that PPR signaling in T cells stimulates the release of TNF (22), 
and that deletion of T cells, T cell production of TNF, or PPR 
signaling in T cells prevents cPTH-induced bone loss (22, 23), as 
effectively as deletion of PPR signaling in osteocytes. Because of 
these reports, T cells are now recognized as a second critical target 
of PTH in bone. Controversy remains on the relative relevance 
of T cells, osteocytes, and osteoblasts for the activity of PTH. 
However, new evidence suggests that PTH expands Th17 cells 
and increases IL-17 levels in mice and humans (24). Studies in the 
mouse of further shown that Th17 cell-produced IL-17 acts as an 
“upstream cytokine” that increases the sensitivity of osteoblasts 
and osteocytes to PTH. As a result, PTH stimulates osteocytic and 
osteoblastic release of RANKL, and thus cause bone loss, only in 
the presence of intact IL-17 signaling. This article focuses on the 
role of Th17 cell-produced IL-17 in the mechanism of action of 
PTH in bone.
tH17 ceLLs AND PtH-iNDUceD BONe 
LOss
The discovery that T lymphocytes express functional PPR (13) 
and respond to PTH (25) prompted investigations on the role of 
T cells as mediators of the effects of cPTH in bone. Early studies 
revealed that levels of PTH typically found in PHPT require the 
presence of T cells to induce bone loss (26, 27), whereas condi-
tions that cause extreme elevations in PTH levels induce bone loss 
via T cell-independent mechanisms (28–31).
T cells exert complex activities that are relevant for the effects 
of PTH in bone, including stimulating the production of TNF 
by both CD4+ and CD8+ T cells (22). Since CD8+ cells are more 
abundant in the BM than CD4+ cells, most of the TNF produced 
in the BM in response to cPTH originates from CD8+ cells (22). 
TNF stimulates osteoclast formation and activity via multiple 
mechanisms, which include increased production of RANKL 
by all osteoblastic cells including osteocytes. Attesting to the 
relevance of T cell produced TNF, cPTH fails to induce bone loss 
and stimulate bone resorption in mice specifically lacking T cell 
TNF production (22). PTH induces T cell production of TNF 
via direct activation of PPR signaling in T cells (22). Conditional 
silencing of the PTH receptor PPR in T cells blunts the stimula-
tion of bone resorption induced by cPTH without affecting bone 
formation, thus blocking cortical bone loss and converting the 
effects of cPTH in trabecular bone from catabolic to anabolic 
(22). These findings demonstrate the critical relevance of direct 
PPR signaling in T cells.
cPTH stimulates bone cells and immune cells to release growth 
factors and cytokines. Among them are TGFβ, IL-6, and TNF (22, 
32–34). TGFβ and IL-6 direct the differentiation of naive CD4+ 
cells into Th17 cells (35–37).
Th17 cells are the most osteoclastogenic subsets of T cells (38). 
Th17 cells are defined by their capacity to produce the cytokine 
IL-17. Th17 cells are constitutively present at mucosal surfaces, 
especially in the intestinal lamina propria (39). Th17 cells play a 
pivotal role in the bone loss of inflammatory conditions such as 
psoriasis, rheumatoid arthritis, periodontal disease, and IBD (40, 
41). Th17 cells potently induce osteoclastogenesis by secreting 
IL-17, RANKL, TNF, IL-1, and IL-6, along with low levels of IFNγ 
(42–44). IL-17 stimulates the release of RANKL by osteoblasts 
and osteocytes (24, 38) and potentiates the osteoclastogenic 
activity of RANKL by upregulating RANK (45). IL-17 provides 
an important connection between T cells and osteocytes as this T 
cell cytokine regulates osteocytic RANKL production (24), which 
is one key effect of PTH on osteocytes (12, 19).
Studies with agents neutralizing TNF have implicated TNF 
in the generation of Th17 cells in rodents and humans (46–48). 
Moreover, PTH binding to PPR activates the G protein-coupled 
receptor subunit GαS, leading to the generation of cAMP (49). 
Accumulation of cAMP in CD4+ cells and the resulting Ca2+ 
influx further promote Th17 cell differentiation and activity (50). 
Therefore, cPTH could expand Th17 cells via several mecha-
nisms. This reasoning prompted investigations on the relation-
ship between cPTH treatment and Th-17. Murine studies have 
revealed that cPTH treatment increases the relative and absolute 
frequency of Th17+ cells and the levels of IL-17 in peripheral blood, 
spleen, and BM (24). Detailed analysis of samples of peripheral 
blood revealed that cPTH increased IL-17 levels in purified 
peripheral blood CD4+ cells and unfractionated peripheral blood 
nucleated cells, but not in CD4+ cell-depleted peripheral blood 
nucleated cells, indicating that CD4+ cells represent the major 
source of IL-17 mRNA in peripheral blood cells. Moreover, cPTH 
also increases the mRNA levels of the Th17-inducing transcrip-
tion factors RORα and RORγt in peripheral blood, spleen, and 
BM CD4+ T cells. This effect of cPTH is specific for Th17 cells 
because cPTH does not expand murine Th1 cells, Th2 cells, and 
regulatory T cells.
Mechanistic studies have disclosed that cPTH increases Th17 
cell differentiation in the BM and the spleen. By contrast, cPTH 
does not stimulate Th17 cell proliferation (24). Surprisingly, these 
studies have shown that cPTH expands Th17 cells and increases 
the production of IL-17 via TNF, and more specifically, the pool 
of TNF produced by conventional CD4+ and CD8+ T cells. This 
conclusion is based on the fact that cPTH failed to expand BM 
and splenic Th17 calls in TNF-null mice and in T cell-null mice 
previously subjected to adoptive transfer of TNF−/− T cells. The 
latter experimental model is particularly significant, because the 
host mice possess all physiologic sources of TNF except for T 
cells. Yet, specific ablation of T cell produced TNF is sufficient 
to block the capacity of cPTH to expand Th17 cells, increase BM 
IL-17 levels and prevent bone loss (24). Additional T cell reconsti-
tution studies revealed that TNF directly targets Th17 precursors. 
To reach this conclusions, investigators reconstituted T cell-null 
mice with CD4+ cells from TNFR1−/− and TNFR2−/− mice and 
then treated the host mice with cPTH. Under these conditions, 
cPTH expanded BM Th17 cells and increase BM IL-17 levels in 
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mice with TNFR2−/− T cells but not in those with TNFR1−/− T 
cells, thus demonstrating that TNFR1 signaling is required for 
cPTH to induce the differentiation of CD4+ cells into Th17 cells. 
In addition to IL-6 TGFβ and TNF, several cytokines are known 
to promote Th17 cell expansion. Among them are the T cell pro-
duced factor IL-21 and the macrophage/dendritic cell produced 
cytokine IL-23. cPTH treatment increases the BM levels of IL-21, 
and IL-23R in WT mice. By contrast, cPTH did not increase the 
levels of these cytokines in TNF−/− mice. Thus, IL-21 and IL-23 
are likely to contribute to expansion of Th17 cells induced by 
cPTH. However, cPTH upregulates these factors via TNF.
As stated above, PTH receptor signaling activates GαS, lead-
ing to the generation of cAMP (49), which further promotes 
TH17 cell differentiation via Ca2+ influx (50). One mechanism 
by which activation of GαS in CD4+ cells could promote Th17 
cell differentiation is increased sensitivity to TNF. To investigate 
this hypothesis, investigators used GαSΔCD4,8 mice, a strain char-
acterized by silenced GαS signaling in CD4+ and CD8+ T cells. 
Pivotal experiments revealed that cultures of CD4+ cells from 
cPTH-treated control mice yielded a higher number of Th17 cells 
as compared to those from vehicle-treated mice (24). By contrast, 
cultures of CD4+ cells from vehicle and cPTH-treated GαSΔCD4,8 
mice yielded similar numbers of Th17 cells, demonstrating that 
cPTH increases the sensitivity of nascent Th17 cells to TNF via 
GαS signaling in CD4+ cells. Attesting to the relevance of GαS 
signaling in CD4+ cells for Th17 cell generation, cPTH was found 
not to expand BM and splenic Th17 cells and not to exerts its bone 
catabolic activity in GαSΔCD4,8 mice, demonstrate that silencing of 
Gαs in T cells prevents the expansion of Th17 cells and the bone 
loss induced by cPTH (24).
Signaling events downstream of GαS include cAMP generation 
(49) and activation of L-type calcium channels (51), which promote 
Th1 and Th17 cell differentiation (50). This evidence suggests the 
possibility that treatment with the L-type calcium channel blocker 
diltiazem may blunt the differentiation of CD4+ cells into Th17 
cells (50) and prevent the bone loss induced by cPTH.
This hypothesis was tested in murine studies that revealed 
that diltiazem blocks the expansion of Th17 cells, the increase 
in bone resorption, and the loss of cortical and trabecular bone 
induced by cPTH. The finding may suggest a potential therapeu-
tic role for L-type calcium channel blockers in the treatment of 
hyperparathyroidism.
NeUtrALiZAtiON OF iL-17A Or 
siLeNciNG OF iL-17rA BLOcK  
cPtH-iNDUceD BONe LOss
The finding that cPTH increases the levels of IL-17 does not dem-
onstrate that IL-17 plays a role in the bone catabolic activity of 
cPTH. To demonstrate the relevance of IL-17 in the mechanism 
by which cPTH alters skeletal homeostasis mice were treated with 
cPTH and a neutralizing antibody directed against murine IL-17 
(IL-17 Ab). These studies revealed that IL-17 Ab completely pre-
vents the loss of cortical and trabecular bone induced by cPTH. 
Analysis of biochemical and histomorphometric indices of bone 
turnover revealed that neutralization of IL-17 blunts the bone 
catabolic activity of cPTH by decreasing bone resorption (24).
To confirm these findings, additional experiments were 
conducted utilizing IL-17RA-null mice, a strain lacking the het-
erodimeric receptor IL-17RA/IL-17RC known as IL-17RA (52, 
53). IL-17 signaling is silenced in IL-17RA−/− mice (54). These 
studies disclosed that cPTH stimulates bone resorption and 
indices bone loss in control mice but not in IL-17RA mice (24), 
thus demonstrating that silencing of IL-17 signaling prevents the 
bone catabolic activity of cPTH.
iL-17 is AN UPstreAM cYtOKiNe 
reQUireD FOr cPtH tO iNcreAse 
rANKL reLeAse BY OsteOBLAsts AND 
OsteOcYtes
Osteocytes and the pool of RANKL produced by osteocytes are 
crucial for the activity of cPTH (12, 19, 20). On the other hand, 
studies form our laboratory have shown T cells are an additional 
important target of PTH (55). The fact that silencing of PPR 
signaling in T cells and osteocytes induces similar bone sparing 
effects is in keeping with a “serial circuit” regulatory model, where 
signals from one population affect the response to cPTH of the 
other. Since T cells and osteocytes have limited physical contacts, 
the cross talk between these populations is likely mediated by a 
soluble factor. IL-17A is a probable candidate because it is a potent 
inducer of RANKL in organ cultures containing osteoblasts and 
osteocytes (56). In support of this hypothesis, investigations have 
shown that neutralization of IL-17 via treatment with IL-17 Ab 
and deletion of IL-17RA block the capacity of cPTH to increase 
the production of RANKL by osteocytes and osteoblasts (24). 
These data indicate that IL-17A increases the sensitivity of 
osteoblasts and osteocytes to cPTH, thus enabling these lineages 
to release RANKL when stimulated by cPTH. Therefore, IL-17 
mediates the bone catabolic activity of cPTH by upregulating the 
production of RANKL by osteocytes and osteoblasts (Figure 1).
It is important to underscore that the available published data 
suggest that T cells, osteoblasts, and osteocytes are all required for 
cPTH and by extension, PHPT, to induce bone loss. By contrast, 
osteocytes, but not T cells and IL-17, are required for physiologic 
levels of endogenous PTH to regulate bone remodeling. In fact, 
mice lacking PPR signaling in osteocytes have high baseline bone 
volume (12), while IL-17RA-null mice and those lacking PPR 
signaling in T cells (22, 57) have a normal bone volume.
iNcreAseD PrODUctiON OF iL-17A iN 
HUMANs AFFecteD BY PriMArY 
HYPerPArAtHYrOiDisM
While numerous studies have investigated the role of immune 
cells and cytokines in the mechanism of action of PTH in animal 
models, little information is available in humans.
To investigate the effects of PHPT on the production of 
cytokines, unfractionated peripheral blood nucleated cells were 
obtained from 57 healthy controls and 20 similar subjects affected 
by PHPT. In PHPT patient’s blood samples were obtained before 
surgery and 1 month after successful resolution of PHPT by par-
athyroidectomy. This study revealed (Figure 2) that the mRNA 
FiGUre 2 | Levels (Median ± interquartile range) of iL-17A (Panel A) 
and rOrc mrNAs (Panel B) in healthy controls (n = 57) and subjects 
with PHPt before (n = 20) and after parathyroidectomy (n = 20). Data 
were analyzed by Mann–Whitney (healthy controls vs. PHPT before surgery 
and healthy controls vs. PHPT after surgery) and Wilcoxon matched pairs 
signed rank tests (PHPT vs. PHPT after surgery) as the data were not 
normally distributed according to the Shapiro–Wilk normality test. 
Reproduced with permission from Ref. (24).
FiGUre 1 | schematic representation of the mechanism of action of 
cPtH in bone. PTH binds to the PTH receptor PPR expressed in 
conventional CD4+ and Cd8+ T cells and induces the secretion of TNF. This 
cytokines induces the differentiation of naive CD4+ cells into Th17 cells via 
TNFR1 signaling. Th17 cells release additional TNF, which further stimulates 
Th17 differentiation. More importantly, Th17 cells secrete IL-17, which targets 
osteocytes and osteoblasts, thus increasing their sensitivity to TNF. In the 
presence of IL-17, PPR activation in osteocytes and osteoblasts stimulates 
these cells to release RANKL, which stimulates bone resorption and induces 
bone loss. Silencing of IL-17 or IL-17RA signaling blocks the capacity of 
cPTH to stimulate the production of RANKL by osteocytes and osteoblasts. 
Reproduced with permission from Ref. (24).
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levels of IL-17A in unfractionated peripheral blood nucleated 
cells were approximately threefold higher in PHPT patients than 
in healthy controls (24). Moreover, surgical restoration of normal 
parathyroid function was associated with the normalization of 
IL-17A levels. Furthermore, the mRNA levels of the IL-17-inducing 
transcription factor RORC were approximately threefold higher 
in PHPT patients before surgery than in healthy controls and 
parathyroidectomy was followed by a decrease in RORC mRNA 
levels. PTH levels were directly correlated with IL-17A level and 
the differences in IL-17A and RORC levels between healthy con-
trols and PHPT patients remained significant even after adjust-
ment for age and gender by a multiple regression model. These 
findings suggest that increased IL-17A gene expression in PHPT 
patients is due to increased levels of circulating PTH.
cONcLUsiON
Remarkable progress has been made in understanding how T cells 
participate in the regulation of bone remodeling in health and dis-
ease. An impressive amount of work published in the last 10 years 
has led to the recognition that T cells play an unexpected role in 
the regulation of bone resorption and bone formation through a 
variety of mechanisms and the involvement of specialized cell line-
ages such as Th17 cells and Tregs. Work remains to be done to fully 
understand the cross-talk between bone cells and immune cells.
Some confirmation of the relevance of T cells in human bone 
diseases has now been reported but much remains to be done. 
Most of the human evidence has been accrued in studies on 
the pathogenesis of postmenopausal osteoporosis. For example, 
evidence begins to emerge in favor of a role of T cell produced 
TNF in postmenopausal bone loss in women (58, 59) and that 
in humans estrogen deficiency expands RANKL-expressing T 
cells and B cells (60, 61). Moreover, a role for IL-1 and TNF 
in humans is supported by reports that menopause increases 
the levels of these factors (62–66), while treatment with inhibi-
tors of IL-1 and TNF prevents the increase in bone resorption 
induced by estrogen deficiency (67). A recent report from 
our laboratory show that PHPT increases IL-17 production 
in humans, an abnormality which is resolved by successful 
parathyroidectomy. Our studies show that in mice, the bone 
loss induced by cPTH is prevented by the calcium channel 
blocker diltiazem, and IL-17 Ab. Direct clinical applications of 
these finding arise because L-type calcium channel blocker are 
available, while anti-human IL-17 Abs and IL-17 receptor Abs 
are under investigation as therapeutic agents in psoriasis and 
spondyloarthropathy (68–71).
February 2016 | Volume 7 | Article 575
Pacifici PTH and T Cells
Frontiers in Immunology | www.frontiersin.org
AUtHOr cONtriBUtiONs
The author confirms being the sole contributor of this work and 
approved it for publication.
AcKNOWLeDGMeNts
This paper was supported by grants from the National Institutes 
of Health (AR54625, DK007298, and RR028009).
reFereNces
1. Riggs BL, Melton LJ. Medical progress: involutional osteoporosis. N Eng J Med 
(1986) 314:1676–84. doi:10.1056/NEJM198606263142605 
2. Grey AB, Stapleton JP, Evans MC, Reid IR. Accelerated bone loss in post- 
menopausal women with mild primary hyperparathyroidism. Clin Endocrinol 
(Oxf) (1996) 44:697–702. doi:10.1046/j.1365-2265.1996.744565.x 
3. Potts J. Primary hyperparathyroidism. In: Avioli LV, Krane S, editors. Metabolic 
Bone Diseases. (Vol. 1), San Diego: Academic Press (1998). p. 411–42.
4. Parisien M, et  al. Histomorphometric analysis of bone in primary hyper-
parathyroidism. In: Belezikian JP, editor. The Parathyroids. Basic and Clinical 
Concepts. San Diego: Academic Press. (2001). p. 423–36.
5. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, et al. 
Skeletal disease in primary hyperparathyroidism. J Bone Miner Res (1989) 
4:283–91. doi:10.1002/jbmr.5650040302 
6. Zhou H, Shen V, Dempster DW, Lindsay R. Continuous parathyroid hormone 
and estrogen administration increases vertebral cancellous bone volume and 
cortical width in the estrogen-deficient rat. J Bone Miner Res (2001) 16:1300–7. 
doi:10.1359/jbmr.2001.16.7.1300 
7. Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, 
et al. On the mechanism of cancellous bone preservation in postmenopausal 
women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 
(1999) 84:1562–6. doi:10.1210/jcem.84.5.5652 
8. Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Moreno A, Dempster DW, 
et al. Short-term continuous infusion of human parathyroid hormone 1-34 
fragment is catabolic with decreased trabecular connectivity density accom-
panied by hypercalcemia in C57BL/J6 mice. J Endocrinol (2005) 186:549–57. 
doi:10.1677/joe.1.06270 
9. Lotinun S, Evans GL, Bronk JT, Bolander ME, Wronski TJ, Ritman EL, 
et al. Continuous parathyroid hormone induces cortical porosity in the rat: 
effects on bone turnover and mechanical properties. J Bone Miner Res (2004) 
19:1165–71. doi:10.1359/JBMR.040404 
10. Hock JM, Gera I. Effects of continuous and intermittent administration and 
inhibition of resorption on the anabolic response of bone to parathyroid 
hormone. J Bone Miner Res (1992) 7:65–72. doi:10.1002/jbmr.5650070110 
11. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, 
et  al. Activated parathyroid hormone/parathyroid hormone-related protein 
receptor in osteoblastic cells differentially affects cortical and trabecular bone. 
J Clin Invest (2001) 107:277–86. doi:10.1172/JCI11296 
12. Saini V, Marengi DA, Barry KJ, Fulzele KS, Heiden E, Liu X, et al. Parathyroid 
hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in 
osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol 
Chem (2013) 288:20122–34. doi:10.1074/jbc.M112.441360 
13. Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, Galley S, et al. T lymphocytes 
amplify the anabolic activity of parathyroid hormone through Wnt10b signal-
ing. Cell Metab (2009) 10:229–40. doi:10.1016/j.cmet.2009.07.010 
14. Cho SW, Soki FN, Koh AJ, Eber MR, Entezami P, Park SI, et al. Osteal macro-
phages support physiologic skeletal remodeling and anabolic actions of para-
thyroid hormone in bone. Proc Natl Acad Sci U S A (2014) 111(4):1545–50. 
doi:10.1073/pnas.1315153111 
15. Weir EC, Lowik CW, Paliwal I, Insogna KL. Colony stimulating factor-1 plays 
a role in osteoclast formation and function in bone resorption induced by 
parathyroid hormone and parathyroid hormone-related protein. J Bone Miner 
Res (1996) 11:1474–81. doi:10.1002/jbmr.5650111014 
16. Ma YL, et  al. Catabolic effects of continuous human PTH (1 – 38) in vivo 
is associated with sustained stimulation of RANKL and inhibition of 
osteoprotegerin and gene-associated bone formation. Endocrinology (2001) 
142:4047–54. doi:10.1210/en.142.9.4047 
17. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword 
for bone metabolism. Trends Endocrinol Metab (2004) 15:60–5. doi:10.1016/j.
tem.2004.01.006 
18. Powell WF Jr, Barry KJ, Tulum I, Kobayashi T, Harris SE, Bringhurst FR, et al. 
Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone 
structure and homeostatic calcemic responses. J Endocrinol (2011) 209:21–32. 
doi:10.1530/JOE-10-0308 
19. Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O’Brien 
CA. Osteocyte-derived RANKL is a critical mediator of the increased bone 
resorption caused by dietary calcium deficiency. Bone (2014) 66C:146–54. 
doi:10.1016/j.bone.2014.06.006 
20. Ben-awadh AN, Delgado-Calle J, Tu X, Kuhlenschmidt K, Allen MR, Plotkin 
LI, et  al. Parathyroid hormone receptor signaling induces bone resorption 
in the adult skeleton by directly regulating the RANKL gene in osteocytes. 
Endocrinology (2014) 155:2797–809. doi:10.1210/en.2014-1046 
21. Fumoto T, Takeshita S, Ito M, Ikeda K. Physiological functions of osteoblast 
lineage and T cell-derived RANKL in bone homeostasis. J Bone Miner Res 
(2014) 29:830–42. doi:10.1002/jbmr.2096 
22. Tawfeek H, Bedi B, Li JY, Adams J, Kobayashi T, Weitzmann MN, et  al. 
Disruption of PTH Receptor 1 in T cells protects against PTH-induced bone 
loss. PLoS One (2010) 5:e12290. doi:10.1371/journal.pone.0012290 
23. Gao Y, Wu X, Terauchi M, Li JY, Grassi F, Galley S, et al. T cells potentiate 
PTH-induced cortical bone loss through CD40L signaling. Cell Metab (2008) 
8:132–45. doi:10.1016/j.cmet.2008.07.001 
24. Li JY, D’Amelio P, Robinson J, Walker LD, Vaccaro C, Luo T, et  al. IL-17A 
is increased in humans with primary hyperparathyroidism and mediates 
PTH-induced bone loss in mice. Cell Metab (2015) 22:799–810. doi:10.1016/j.
cmet.2015.09.012 
25. Stojceva-Taneva O, Fadda GZ, Smogorzewski M, Massry SG. Parathyroid hor-
mone increases cytosolic calcium of thymocytes. Nephron (1993) 64:592–9. 
doi:10.1159/000187406 
26. Hory BG, Roussanne MC, Rostand S, Bourdeau A, Drüeke TB, Gogusev 
J. Absence of response to human parathyroid hormone in athymic mice grafted 
with human parathyroid adenoma, hyperplasia or parathyroid cells maintained 
in culture. J Endocrinol Invest (2000) 23:273–9. doi:10.1007/BF03343723 
27. Strieth S, von Johnston V, Eichhorn ME, Enders G, Krasnici S, Thein E, et al.  
A new animal model to assess angiogenesis and endocrine function of parathy-
roid heterografts in vivo. Transplantation (2005) 79:392–400. doi:10.1097/01.
TP.0000151633.92173.75 
28. Schachter P, Christy MD, Leight GS Jr, Lobaugh B. Function in athymic nude 
mice of parathyroid heterografts from patients with primary hyperparathy-
roidism and secondary hyperparathyroidism. Surgery (1990) 108:1040–6. 
29. Guise TA, Chirgwin JM, Favarato G, Boyce BF, Mundy GR. Chinese hamster 
ovarian cells transfected with human parathyroid hormone-related protein 
cDNA cause hypercalcemia in nude mice. Lab Invest (1992) 67:477–85. 
30. Mehdizadeh S, Alaghband-Zadeh J, Gusterson B, Arlot M, Bradbeer JN, 
Loveridge N. Bone resorption and circulating PTH-like bioactivity in an ani-
mal model of hypercalcaemia of malignancy. Biochem Biophys Res Commun 
(1989) 161:1166–71. doi:10.1016/0006-291X(89)91364-8 
31. Uy HL, Guise TA, De La Mata J, Taylor SD, Story BM, Dallas MR, et al. Effects 
of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and 
osteoclast precursors in vivo. Endocrinology (1995) 136:3207–12. doi:10.1210/
en.136.8.3207 
32. Lowik CWGM, et al. Parathyroid hormone (PTH) and PTH-like protein (PLP) 
stimulate IL-6 production by osteogenic cells: a possible role of interleukin-6 
in osteoclastogensis. Biochem Biophys Res Commun (1989) 162:1546–52. 
doi:10.1016/0006-291X(89)90851-6 
33. Koh AJ, Novince CM, Li X, Wang T, Taichman RS, McCauley LK. An irra-
diation-altered bone marrow microenvironment impacts anabolic actions of 
PTH. Endocrinology (2011) 152:4525–36. doi:10.1210/en.2011-1515 
34. Cho SW, Pirih FQ, Koh AJ, Michalski M, Eber MR, Ritchie K, et al. The soluble 
interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of 
parathyroid hormone. J Biol Chem (2013) 288(10):6814–25. doi:10.1074/jbc.
M112.393363 
February 2016 | Volume 7 | Article 576
Pacifici PTH and T Cells
Frontiers in Immunology | www.frontiersin.org
35. Bettelli E, et  al. Reciprocal developmental pathways for the generation of 
pathogenic effector TH17 and regulatory T cells. Nature (2006) 441:235–8. 
doi:10.1038/nature04753 
36. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, 
et al. Transforming growth factor-beta induces development of the T(H)17 
lineage. Nature (2006) 441:231–4. doi:10.1038/nature04754 
37. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in 
the context of an inflammatory cytokine milieu supports de novo differenti-
ation of IL-17-producing T cells. Immunity (2006) 24:179–89. doi:10.1016/j.
immuni.2006.01.001 
38. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. 
Th17 functions as an osteoclastogenic helper T cell subset that links T cell 
activation and bone destruction. J Exp Med (2006) 203:2673–82. doi:10.1084/
jem.20061775 
39. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, 
et  al. The orphan nuclear receptor RORgammat directs the differentiation 
program of proinflammatory IL-17+ T helper cells. Cell (2006) 126:1121–33. 
doi:10.1016/j.cell.2006.07.035 
40. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N 
Engl J Med (2009) 361:888–98. doi:10.1056/NEJMra0707449 
41. Martinez GJ, Nurieva RI, Yang XO, Dong C. Regulation and function of proin-
flammatory TH17 cells. Ann N Y Acad Sci (2008) 1143:188–211. doi:10.1196/
annals.1443.021 
42. Komatsu N, Takayanagi H. Autoimmune arthritis: the interface between the 
immune system and joints. Adv Immunol (2012) 115:45–71. doi:10.1016/
B978-0-12-394299-9.00002-3 
43. Waisman A. T helper cell populations: as flexible as the skin? Eur J Immunol 
(2011) 41:2539–43. doi:10.1002/eji.201141938 
44. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang 
M, et al. IL-17 stimulates the production and expression of proinflammatory 
cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol (1998) 
160:3513–21. 
45. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura 
Y, et  al. Interleukin-17A upregulates receptor activator of NF-kappaB on 
osteoclast precursors. Arthritis Res Ther (2010) 12:R29. doi:10.1186/ar2936 
46. Nakae S, Suto H, Berry GJ, Galli SJ. Mast cell-derived TNF can promote Th17 
cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. 
Blood (2007) 109:3640–8. doi:10.1182/blood-2006-09-046128 
47. Chen DY, et al. Increasing levels of circulating Th17 cells and interleukin-17 in 
rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha 
therapy. Arthritis Res Ther (2011) 13:R126. doi:10.1186/ar3431 
48. Sugita S, et al. Inhibition of Th17 differentiation by anti-TNF-alpha therapy 
in uveitis patients with Behcet’s disease. Arthritis Res Ther (2012) 14:R99. 
doi:10.1186/ar3824 
49. Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell 
Signal (2009) 21:1245–54. doi:10.1016/j.cellsig.2009.02.012 
50. Li X, et al. Divergent requirement for Galphas and cAMP in the differentiation 
and inflammatory profile of distinct mouse Th subsets. J Clin Invest (2012) 
122:963–73. doi:10.1172/JCI59097 
51. Hell JW. Beta-adrenergic regulation of the L-type Ca2+ channel Ca(V)1.2 
by PKA rekindles excitement. Sci Signal (2010) 3:e33. doi:10.1126/
scisignal.3141pe33 
52. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of 
interleukin-17 family members. Immunity (2011) 34:149–62. doi:10.1016/j.
immuni.2011.02.012 
53. Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoim-
mune demyelinating disease. Trends Immunol (2011) 32:232–9. doi:10.1016/j.
it.2011.02.007 
54. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger 
P, et  al. Requirement of interleukin 17 receptor signaling for lung CXC 
chemokine and granulocyte colony-stimulating factor expression, neutrophil 
recruitment, and host defense. J Exp Med (2001) 194:519–27. doi:10.1084/
jem.194.4.519 
55. Pacifici R. Role of T cells in the modulation of PTH action: physiological 
and clinical significance. Endocrine (2013) 44:576–82. doi:10.1007/
s12020-013-9960-8 
56. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, 
et al. Protein expression and functional difference of membrane-bound and 
soluble receptor activator of NF-kappaB ligand: modulation of the expression 
by osteotropic factors and cytokines. Biochem Biophys Res Commun (2000) 
275:768–75. doi:10.1006/bbrc.2000.3379 
57. Bedi B, Li JY, Tawfeek H, Baek KH, Adams J, Vangara SS, et al. Silencing of 
parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic 
activity of PTH. Proc Natl Acad Sci U S A (2012) 109:E725–33. doi:10.1073/
pnas.1120735109 
58. D’Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone 
C, et  al. Estrogen deficiency increases osteoclastogenesis up-regulating T 
cells activity: a key mechanism in osteoporosis. Bone (2008) 43:92–100. 
doi:10.1016/j.bone.2008.02.017 
59. Adeel S, Singh K, Vydareny KH, Kumari M, Shah E, Weitzmann MN, et al. 
Bone loss in surgically ovariectomized premenopausal women is associated 
with T lymphocyte activation and thymic hypertrophy. J Investig Med (2013) 
61:1178–83. doi:10.231/JIM.0000000000000016 
60. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role 
of RANK ligand in mediating increased bone resorption in early postmeno-
pausal women. J Clin Invest (2003) 111:1221–30. doi:10.1172/JCI200317215 
61. Taxel P, Kaneko H, Lee SK, Aguila HL, Raisz LG, Lorenzo JA. Estradiol rapidly 
inhibits osteoclastogenesis and RANKL expression in bone marrow cultures 
in postmenopausal women: a pilot study. Osteoporos Int (2008) 19:193–9. 
doi:10.1007/s00198-007-0452-7 
62. Pacifici R, Rifas L, McCracken R, Vered I, McMurtry C, Avioli LV, et  al. 
Ovarian steroid treatment blocks a postmenopausal increase in blood 
monocyte interleukin 1 release. Proc Natl Acad Sci U S A (1989) 86:2398–402. 
doi:10.1073/pnas.86.7.2398 
63. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, et al. 
Effect of surgical menopause and estrogen replacement on cytokine release 
from human blood mononuclear cells. Proc Natl Acad Sci U S A (1991) 
88:5134–8. doi:10.1073/pnas.88.12.5134 
64. Cohen-Solal ME, Graulet AM, Denne MA, Gueris J, Baylink D, de Vernejoul 
MC. Peripheral monocyte culture supernatants of menopausal women can 
induce bone resorption: involvement of cytokines. J Clin Endocrinol Metab 
(1993) 77:1648–53. doi:10.1210/jcem.77.6.8263153 
65. Cohen-Solal ME, Graulet AM, Gueris J, Denne MA, Bergot C, Morieux C, 
et  al. Bone resorption at the femoral neck is dependent on local factors in 
nonosteoporotic late postmenopausal women: an in vitro-in vivo study. J Bone 
Miner Res (1995) 10:307–14. doi:10.1002/jbmr.5650100219 
66. Bernard-Poenaru O, Roux C, Blanqué R, Gardner C, de Vemejoul MC, Cohen-
Solal ME. Bone-resorbing cytokines from peripheral blood mononuclear 
cells after hormone replacement therapy: a longitudinal study. Osteoporos Int 
(2001) 12:769–76. doi:10.1007/s001980170054 
67. Charatcharoenwitthaya N, et al. Effect of blockade of tumor necrosis factor- 
alpha and interleukin-1 action on bone resorption in early postmenopausal 
women. J Bone Miner Res (2007) 22(5):724–9. doi:10.1359/jbmr.070207 
68. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, 
et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque 
psoriasis. N Engl J Med (2012) 366:1190–9. doi:10.1056/NEJMoa1109997 
69. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar 
A, et  al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic 
arthritis. N Engl J Med (2014) 370:2295–306. doi:10.1056/NEJMoa1315231 
70. Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 
immune axis as a promising new target in the treatment of spondyloarthritis. 
Curr Opin Rheumatol (2014) 26:361–70. doi:10.1097/BOR.0000000000000069 
71. Martin DA, Churchill M, Flores-Suarez L, Cardiel MH, Wallace D, Martin 
R, et al. A phase Ib multiple ascending dose study evaluating safety, pharma-
cokinetics, and early clinical response of brodalumab, a human anti-IL-17R 
antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 
(2013) 15:R164. doi:10.1186/ar4347 
Conflict of Interest Statement: The author declares that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Pacifici. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
